• Safe and Intriguing ‘Nature’s Drugs’ Taking on Complex Diseases

    Clinical Research News | The cost of bringing a drug to market has, by some estimates, ballooned to $3 billion and the central problem could be the “misapplication of technology.” Since completion of the Human Genome Project, the focus had shifted heavily toward orphan drugs with a single genetic target, suitable only to highly targeted genetic technology platforms.

    Aug 6, 2024

  • Leveraging Advanced Technologies for Clinical Trial Success

    Clinical Research News | Clinical trials are a crucial step to advancing healthcare and bringing new treatments to patients. However, drug development is a lengthy, expensive, and high-risk proposition, and, according to PhRMA, a process that can take up to 15 years with an average cost exceeding $2 billion per new medicine.

    Aug 2, 2024

  • Trials ‘Still Largely White and Largely Male’ Due to Hidden Biases

    Clinical Research News | Randomized clinical trials (RCTs) may need some serious revamping, based on mounting evidence of systemic biases afflicting the entire enterprise. Despite decades of efforts to realize equitable participation by marginalized groups, notably women and people of color, RCTs are “still largely white and largely male.”

    Jul 31, 2024

  • Youth Diabetes Researchers Invited to Dip Into POND, Make a Hypothesis

    Clinical Research News | Soaring rates of youth prediabetes and diabetes over the past few decades have prompted a multidisciplinary team of experts from the Icahn School of Medicine at Mount Sinai (ISMMS) to create a dataset unifying potentially important clues about how to personalize interventions and devise better prevention strategies.

    Jul 30, 2024

  • Walgreens Receives Project Award, Oracle Announces New AI Capabilities for Trials, N-Power, Merck Collaborate on Oncology Clinical Research, More

    Clinical Research News | Walgreens received a project award valued up to $25 million through the Rapid Response Partnership Vehicle to conduct a Phase IV observational clinical study focused on assessing Correlates of Protection; Oracle announced new capabilities in its AI-supported Oracle Argus and Safety One Intake solutions to help life science organizations meet evolving regulatory requirements and the rising volume of adverse event case workloads; Merck and N-Power Medicine has collaborated to enable a greater number of oncologists—and the patients they care for—to participate in clinical research; and more.

    Jul 25, 2024

  • Cardurion Pharmaceuticals’ Cardiovascular Trials, Cancer Resisting Monoclonal Antibodies, More

    Clinical Research News | Cardurion Pharmaceuticals raises $260 million to support later-stage clinical trials with the company’s two lead drug candidates; CatalYm adds $150 million for phase 2b studies targeting checkpoint-naive and second-line treatment settings for solid tumors; and more.

    Jul 24, 2024